Gilead combo hepatitis C pill shown effective in small trial

Thu May 2, 2013 10:01am EDT

Related Topics

May 2 (Reuters) - Gilead Sciences Inc on Thursday said almost all patients taking a fixed-dose combination of two of its experimental hepatitis C drugs appeared to have eliminated the liver virus after either 8 weeks or 12 weeks of treatment in a small mid-stage study.

The data could help Gilead, whose shares rose 4 percent, remain in the lead among drugmakers racing to develop better medicines for the potentially dangerous condition that also require far shorter durations of treatment.

Based on the favorable results, Gilead said it plans to conduct a third late-stage study of the fixed-dose combination tablet, which pairs the drugs sofosbuvir and ledipasvir. (Reporting By Ransdell Pierson; Editing by Gerald E. McCormick)

FILED UNDER:
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (1)
jimmajors wrote:
as a liver transplant patient i am very glad to hear that a interferon free treatment option is on the horizon.

May 02, 2013 11:08am EDT  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

A tourist takes a plunge as she swims at Ngapali Beach, a popular tourist site, in the Thandwe township of the Rakhine state, October 6, 2013. Picture taken October 6, 2013. REUTERS/Soe Zeya Tun (MYANMAR - Tags: SOCIETY) - RTR3FOI0

Where do you want to go?

We look at when to take trips, budget considerations and the popularity of multigenerational family travel.   Video